<DOC>
	<DOCNO>NCT00541034</DOCNO>
	<brief_summary>RATIONALE : Pentostatin may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving pentostatin together cyclophosphamide rituximab may kill cancer cell . PURPOSE : This phase II trial study side effect well give pentostatin together cyclophosphamide rituximab work treat patient previously untreated chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Pentostatin , Cyclophosphamide , Rituximab Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To determine frequency response patient previously untreated , intermediate- high-risk B-cell chronic lymphocytic leukemia ( CLL ) treat pentostatin , cyclophosphamide , rituximab . - To characterize toxicity regimen patient . OUTLINE : Patients receive cyclophosphamide IV follow pentostatin IV day 1 course 1 . Beginning course 2 subsequent course , patient receive cyclophosphamide IV day 1 , pentostatin IV day 1 , rituximab IV day 1 day 1 2 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow least every 3 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) , evidence absolute lymphocytosis blood least 5,000 lymphocyte per microliter OR bone marrow lymphocytosis ≥ 30 % nucleated cell Previously untreated disease Meets 1 follow risk criterion define threestage Rai system Intermediaterisk disease Must meet criterion active disease define NCI Working Group guideline include follow : Weight loss Fatigue Fevers Evidence progressive marrow failure Splenomegaly Progressive lymphadenopathy Progressive lymphocytosis rapid doubling time Highrisk disease Malignant lymphocytes must demonstrate Bcells via immunophenotypic immunohistochemical analysis Patients small lymphocytic lymphoma ( CLL type ) eligible PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 60100 % Total bilirubin ≤ 2.0 mg/dL ( patient Gilbert disease autoimmune hemolytic anemia evaluation cause hyperbilirubinemia , none find may enrol regardless serum bilirubin ) Total creatinine ≤ 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Fertile patient must use effective contraception Patients autoimmune hemolytic anemia autoimmune thrombocytopenia eligible treatment protocol regardless disease stage Exclusion criterion : Significant active infection Ongoing hepatitis B infection , specifically hepatitis B antigen surface antigen positivity Patients hepatitis B antibody positive eligible protocol PRIOR CONCURRENT THERAPY : Concurrent prednisone allow provide used brief course ( ≤ 7 day ) inflammatory condition unrelated CLL No prior cytotoxic therapy rituximab cancer No concurrent radiotherapy chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>